Patients taking Rexulti (brexpiprazole) have filed claims Otsuka Pharmaceuticals for marketing and distributing the antipsychotic drug, alleging injuries and certain compulsive behaviors have been directly caused by or exacerbated by Rexulti.
Lawyers argue that the drug, similar to Abilify, is linked to severe compulsive gambling addiction and other compulsive behavior disorders like compulsive shopping, eating or sexual behavior. In February 2018, Otsuka added compulsive gambling and other compulsive behavior disorders as risks associated with taking the drug to the Rexulti label.
Rexulti is prescribed to treat schizophrenia and major depressive disorder (MDD). The medication is meant to rebalance dopamine and serotonin to improve thinking, mood, and behavior.
Rexulti is an antipsychotic medication sold by Otsuka Pharmaceutical Co., the same drug manufacturer of Abilify (aripiprazole), a drug targeted by product liability lawyers and Ohio pharmaceutical attorneys for its association with compulsive behavior.
Joe Lyon is a highly-rated Cincinnati Product Liability lawyer and Ohio pharmaceutical attorney representing plaintiffs nationwide in a wide variety of settlement claims against pharmaceutical companies like Otsuka.
Around the same time Abilify lost its patent protection, Otsuka created a similar medication called brexpiprazole and sold it under the name Rexulti. Rexulti and Abilify are quite similar, and designed to treat the same conditions and mood disorders like schizophrenia.
The troubling issue is that Abilify has harmed patients, yet a similar drug has still been approved and released. Both Rexulti and Abilify carry a risk of compulsive behavior side effects, particularly a compulsive gambling addiction.
A current class action lawsuit contends that Rexulti is linked to compulsive gambling, compulsive sexual behavior, compulsive shopping, compulsive eating and other compulsive behavior. The drug may also be linked to suicidal thoughts, as well as acute dyskinesias and dystonic reactions, Parkinsonism, akinesia, and neuroleptic malignant syndrome.
In May 2016, the U.S. Food and Drug Administration (FDA) warned that the antipsychotic drug, Abilify, may be linked to impulse-control side effects like severe urges to gamble, eat, shop, and have sex.
Doctors have stated that expected complications include weight gain, restlessness, and an increase in suicidal thought and behaviors among youths. But an impulse-control disorder has been understated by the drug maker and the FDA.
Rexulti users have been reported experiencing compulsive behaviors, including gambling and hyper-sexuality. The FDA issued a warning that anyone taking certain antipsychotic medications can be affected by a compulsion to gamble, drink alcohol, shop excessively, as well as exhibit a hyper-sexuality. In studies, reducing a dose or discontinuing the antipsychotic resolve the urges or compulsions.
Recent studies suggest that the antipsychotic class of drugs may have unintentional effects on patients, especially adolescents and geriatric patients. An FDA review of clinical trials prompted several “Black Box” warnings for some antipsychotic drugs, including Rexulti.
The FDA warns patients that Rexulti is not approved for dementia-related psychosis, and that there is an increased mortality risk in elderly dementia patients on antipsychotic drugs. The FDA has also warned of the Rexulti risks on Suicidality in children and teens with depressive or psychiatric disorders.
Pharmaceutical companies have a long history of failing to properly test drugs before releasing them, and downplaying the risks of their defective products.
ABOUT THE LYON FIRM
Joseph Lyon has 17 years of experience representing individuals in complex litigation matters. He has represented individuals in every state against many of the largest companies in the world.
The Firm focuses on single-event civil cases and class actions involving corporate neglect & fraud, toxic exposure, product defects & recalls, medical malpractice, and invasion of privacy.
NO COST UNLESS WE WIN
The Firm offers contingency fees, advancing all costs of the litigation, and accepting the full financial risk, allowing our clients full access to the legal system while reducing the financial stress while they focus on their healthcare and financial needs.
By taking the initiative and filing drug injury lawsuits, plaintiffs can receive proper compensation and hold a corporation accountable for their negligent actions. Consumer safety depends largely on making sure drug companies operate within the law and within ethical boundaries.
When drug makers and large corporations are negligent and produce dangerous products that lead to serious illness and injury, legal action can be necessary. In the current corporate environment, filing a Rexulti lawsuit is one of the only ways to keep drug companies from selling untested and dubious pharmaceuticals in the name of profit.
Pharmaceutical litigation helps bring awareness to these companies as to the necessary changes that need to occur in order to keep people safe a healthy while taking a certain drug.
By taking the initiative and filing a Rexulti injury lawsuit, plaintiffs can receive proper compensation and hold a corporation accountable for their negligent actions. Consumer safety depends largely on making sure companies operate within the law and within ethical boundaries.
In past litigation, it has been discovered that drug companies often delay adding serious side effects to a drug’s label due to concerns about the impact on the sales and marketing. If a drug carries more serious side effects, physicians and patients look for alternative treatments with less risk and the same or similar benefit. As a result, there is a financial incentive not to strengthen the warning label.
However, the label is the source of information that physicians and patients rely upon when making these important health decisions. There is no excuse for a company not to update its label when the science is sufficient to show an association with the medication.
The FDA has not issued any recalls for the drug, however, they did add a “Black Box Warning,” which is a strong suggestion that the drug may be dangerous for some patients.
Pharmaceutical litigation is a complex area of law that combines dense regulation, developing science, and multi-jurisdictional questions of law. Most Rexulti cases involving claims of drug injury become centralized in the federal multidistrict litigation process.
Due to the volume of cases and number of similar issues, most Rexulti cases are handled through Multidistrict Litigation (MDL). The multidistrict litigation procedure is guided by the Judicial Panel for Multidistrict Litigation, where the case is centralized before one federal Judge for the purposes of pre-trial discovery.
The MDL process is appropriate where there are one or more common questions of fact in multiple cases pending in different federal district courts. While there often are parallel state consolidated proceedings, the federal MDL process is generally supported by both Plaintiff and Defendants in these cases.
The MDL process allows for efficiency where there are millions of pages of documents, many expert witnesses across multiple disciplines from epidemiology, pharmacology, toxicology and the specific discipline for the relevant mechanism of injury.
Although 28 USC 1407 does not specify a specific number of cases required before the formation of an MDL is appropriate, the Judicial Panel for Multidistrict Litigation reviews the Motions and conducts a hearing to determine whether consolidation is ripe given the number and location of the pending Rexulti cases.
Following drug injury, The Lyon Firm aggressively, professionally, and passionately advocates for injured individuals and families against companies due to a drug to obtain just compensation under the law.
Nationwide Consolidation in U.S. District Court, E. Dist. of LA.
This pharmaceutical case involved claims that the blockbuster painkiller was causing heart attacks and strokes in consumers. The FDA ultimately recalled the medication. Merck settled the outstanding Vioxx claims for $4.85 billion following multiple trials in both state and federal courts. Joe Lyon was co-counsel in a number of individual claims that were successfully resolved in the federal MDL. The funds received for Lyon Firm clients helped several elderly clients with additional medical and home healthcare.
Nationwide Consolidation in Civil Complex Litigation Center Philadelphia, PA.
A pharmaceutical case involving claims that a popular surgical medication was causing kidney failure and death. The FDA recalled the medication in question, but not before thousands of patients died due to related complications. Bayer resolved certain claims for $60 Million for patients who suffered kidney failure and death as a result of using the drug Trasylol. Joseph Lyon represented a widow from Kentucky whose husband died due to kidney failure following the administration of Trasylol. The recovered funds assisted the surviving family members in resuming farming operations.